Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Orexo Ab (ORXOY)

Orexo Ab (ORXOY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 13.01
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (N/A)
  • Most Recent Dividend N/A on N/A
  • Sector N/A
  • INDUSTRY GROUPING N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.7500 +9.09%
on 11/07/25
3.0000 unch
on 11/21/25
-1.0000 (-25.00%)
since 10/13/25
3-Month
2.2300 +34.53%
on 09/05/25
4.0500 -25.93%
on 10/07/25
+1.0900 (+57.07%)
since 08/15/25

Most Recent Stories

More News
Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication

UPPSALA, Sweden , Sept. 5, 2025 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announced positive pharmacokinetic in-vivo data for a powder-based intranasal semaglutide...

ORXOY : 3.0000 (+3.45%)
ORXOF : 3.0500 (+5.17%)
Orexo announces data from the MODIA® study evaluating impact on use of illicit opioids

The six-month randomized controlled trial (RCT) enrolled 437 participants at 36 sites across the US The study demonstrated no statistically significant...

ORXOY : 3.0000 (+3.45%)
Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose

/PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces the submission of the New Drug Application (NDA) to the US Food and Drug...

ORXOY : 3.0000 (+3.45%)
Orexo to participate in Pareto Securities´ 14th Annual Healthcare Conference 2023

/PRNewswire/ -- Orexo AB (Publ.), (STO:ORX) (OTCQX:ORXOY), today announces the company will participate in Pareto Securities' 14th Annual Healthcare...

ORXOY : 3.0000 (+3.45%)
Orexo secures patent protection in the US for OX640, a nasal epinephrine powder product

/PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces that the United States Patent and Trademark Office (USPTO) has granted the first US...

ORXOY : 3.0000 (+3.45%)
Orexo's patent win for ZUBSOLV® appealed

/PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces that Sun Pharmaceutical Industries Limited, Sun Pharma Global FZE, Sun Pharma...

ORXOY : 3.0000 (+3.45%)
Orexo wins patent litigation for ZUBSOLV® in the US

/PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces that the US District Court for the District of New Jersey ruled in favor of Orexo...

ORXOY : 3.0000 (+3.45%)
Orexo shares new timeline for the high-dose rescue medication for opioid overdose, OX124

/PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces the expected US launch of OX124, a high-dose rescue medication for opioid overdose,...

ORXOY : 3.0000 (+3.45%)
Orexo postpones publication of the Annual Report

/PRNewswire/ -- Orexo AB (publ), (STO:ORX) (OTCQX:ORXOY), has resolved to postpone the publication of the Annual Report for 2022 to March 28, 2023. The...

ORXOY : 3.0000 (+3.45%)
Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose

/PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces the submission of a New Drug Application (NDA) to the US Food and Drug...

ORXOY : 3.0000 (+3.45%)

Business Summary

Orexo AB is a pharmaceutical company. It develops and improves products and treatments based on proprietary drug delivery technology. Its main products are Abstral, Edluar, Diabact UBT, and Heliprobe System. Abstral is a drug that provides fast and effective treatment of breakthrough pain in cancer patients....

See More

Key Turning Points

3rd Resistance Point 3.0000
2nd Resistance Point 3.0000
1st Resistance Point 3.0000
Last Price 3.0000
1st Support Level 3.0000
2nd Support Level 3.0000
3rd Support Level 3.0000

See More

52-Week High 4.0500
Fibonacci 61.8% 3.2325
Last Price 3.0000
Fibonacci 50% 2.9800
Fibonacci 38.2% 2.7275
52-Week Low 1.9100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar